Q1 FY2026 · ended Mar 31, 2026 · Revenue $0 · Filed Aug 14, 2026
TuHURA BIOSCIENCES, INC./NV (HURA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$8.8 million. As of Jun 30, 2026 it held $995,977 in cash and investments and $4.0 million in total debt.
Revenue
$0
Net income
$-9.22M
+3.2% vs year-ago quarter
Operating cash flow
$-8.63M
-38.2% vs year-ago quarter
Free cash flow
$-8.77M
-40.2% vs year-ago quarter
EPS
$-0.14
+33.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
63.73M
+27.3% vs year-ago quarter
Net cash
$-3.01M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1498382
- Former names
- Kintara Therapeutics, Inc. (until Oct 22, 2024); DelMar Pharmaceuticals, Inc. (until Aug 18, 2020); Berry Only Inc. (until Jan 18, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Net income | -$9.2M | -$7.5M | -$6.8M | -$7.1M | -$9.5M |
| Diluted EPS | -$0.14 | -$0.13 | -$0.13 | -$0.14 | -$0.21 |
| Operating cash flow | -$8.6M | -$4.4M | -$5.6M | -$11.1M | -$6.2M |
| Free cash flow | -$8.8M | -$4.5M | -$5.6M | -$11.1M | -$6.3M |
| Total assets | $31.7M | $29.7M | $27.4M | $25.7M | $34.6M |
| Total liabilities | $13.2M | $6.5M | $6.4M | $8.9M | $15.2M |
| Stockholders' equity | $18.5M | $23.2M | $20.9M | $16.8M | $19.4M |
| Cash and investments | $995,977 | $6.3M | $3.6M | $2.7M | $8.5M |
| Total debt | $4.0M | $456,926 | $502,668 | $84,346 | $124,969 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
New debt
|
Oct 16, 2026 | Oct 9, 2026 |
| 8-K |
Current report
New debt
|
Sep 24, 2026 | Sep 21, 2026 |
| 8-K |
Current report
New debt
|
Sep 17, 2026 | Sep 14, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Sep 17, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 10, 2026 |
| 8-K |
Current report
New debt
|
Sep 4, 2026 | Sep 2, 2026 |
All 928 TuHURA BIOSCIENCES, INC./NV SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.